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Abstract 
Modulation of transforming growth factor-β (TGF-β) signaling to promote muscle growth holds 
tremendous promise for the muscular dystrophies and other disorders involving the loss of functional 
muscle mass. Previous studies have focused on the TGF-β family member myostatin and demonstrated 
that inhibition of myostatin leads to muscle growth in normal and dystrophic mice. We describe a unique 
method of systemic inhibition of activin IIB receptor signaling via adeno-associated virus (AAV)-mediated 
gene transfer of a soluble form of the extracellular domain of the activin IIB receptor to the liver. 
Treatment of mdx mice with activin IIB receptor blockade led to increased skeletal muscle mass, 
increased force production in the extensor digitorum longus (EDL), and reduced serum creatine kinase. 
No effect on heart mass or function was observed. Our results indicate that activin IIB receptor blockade 
represents a novel and effective therapeutic strategy for the muscular dystrophies. 
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Abstract
Modulation of transforming growth factor-β (TGF-β) signaling to promote muscle growth holds 
tremendous promise for the muscular dystrophies and other disorders involving the loss of 
functional muscle mass. Previous studies have focused on the TGF-β family member myostatin 
and demonstrated that inhibition of myostatin leads to muscle growth in normal and dystrophic 
mice. We describe a unique method of systemic inhibition of activin IIB receptor signaling via 
adeno-associated virus (AAV)-mediated gene transfer of a soluble form of the extracellular 
domain of the activin IIB receptor to the liver. Treatment of mdx mice with activin IIB receptor 
blockade led to increased skeletal muscle mass, increased force production in the extensor 
digitorum longus (EDL), and reduced serum creatine kinase. No effect on heart mass or function 
was observed. Our results indicate that activin IIB receptor blockade represents a novel and 
effective therapeutic strategy for the muscular dystrophies.
Keywords
activin IIB receptor; adenoassociated virus; gene therapy; muscular dystrophy; transforming 
growth factor-β
Duchenne muscular dystrophy is characterized by progressive deterioration of skeletal 
muscle due to the absence of dystrophin. Although no definitive treatment is yet available, 
Correspondence to: K.J. Morine; km446@drexel.edu. 
HHS Public Access
Author manuscript
Muscle Nerve. Author manuscript; available in PMC 2015 July 17.
Published in final edited form as:













considerable attention has been devoted to treatments that increase functional muscle mass 
by enhancing growth or preventing breakdown. As dystrophic muscle is inherently 
susceptible to contraction-induced damage, it is conceivable that increasing muscle mass 
would reduce relative load on the muscle and decrease damage during routine use. Two 
approaches that have been previously explored in non-dystrophic mice to induce muscle 
hypertrophy include increased expression of insulinlike growth factor-1 (IGF-1), a positive 
growth factor, and inhibition of myostatin, a negative growth factor.1,2 Although we and 
others have successfully exploited the myostatin signaling pathways to ameliorate murine 
dystrophic pathology it is unclear if these results translate to humans.3–5 Indeed, a recent 
clinical trial that utilized a recombinant myostatin antibody failed to demonstrate clinical 
improvement in adult muscular dystrophies.6 Novel strategies that promote muscle growth 
may be beneficial for treatment of the muscular dystrophies as well as disuse atrophy, 
sarcopenia, cachexia, and other muscle wasting disorders.
The transforming growth factor-β (TGF-β) superfamily of growth factors are circulating 
polypeptides implicated in the control of diverse biological functions. Members of the TGF-
β family act as ligands for heteromers of membrane-associated type I and II receptors, which 
possess cytoplasmic serine/threonine kinase domains.7 These domains phosphorylate and 
activate intracellular mediators such as the Smads, which translocate to the nucleus upon 
activation and directly modulate transcription.8 More than 30 TGF-β ligands have been 
identified. Only five type II receptors have been characterized, which indicates each type II 
receptor mediates signaling for multiple ligands.9 The type II receptors for activin include 
activin IIAr and IIBr.10,11 These receptors have generated considerable interest for their 
widespread involvement in embryonic development and postnatal regulation of varied 
processes, including osteogenesis, vasculogenesis, and skeletal muscle growth.12 In the 
developing mouse, the activin IIB receptor is expressed in the embryonic ectoderm during 
gastrulation and has been detected in a variety of embryonic organs, including the brain, 
stomach, and metanephros.11,13 Absence of the activin IIB receptor in transgenic mice leads 
to patterning defects and is perinatally lethal secondary to cardiovascular abnormalities in 
the majority of receptor-deficient mice.14 The in vivo ligands for activin IIBr include 
activin, inhibin, members of the bone morphogenetic protein (BMP) family, myostatin, and 
growth and differentiation factor 11 (GDF11).15,16
The control mechanism of muscle growth by activin receptor signaling pathways is not 
completely defined. Through various experimental modalities and multiple animal models, 
myostatin genetic deletion or postnatal inhibition results in muscle growth.2,3,17 
Interestingly, myostatin knockout mice gained an additional 15–26% of muscle mass when 
injected with a soluble form of the activin IIB receptor.18 Further, muscle mass is nearly 
quadrupled in a transgenic cross between the myostatin knockout and a skeletal muscle 
specific overexpression of follistatin.19 Thus, there is at least one other circulating factor 
that signals through the activin IIB receptor and negatively regulates muscle mass. Affinity 
purification studies of mouse and human serum utilizing the activin IIB receptor as bait 
revealed that activin A/B, GDF8/myostatin, and GDF11 circulate in normal serum and are 
capable of blocking in vitro myoblast differentiation.16 Of these factors, only myostatin has 
conclusively been shown to regulate muscle mass in vivo. GDF11 is unlikely to be a 
candidate negative regulator, as the skeletal muscle specific loss of GDF11 did not affect 
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muscle size.20 A recent study showed a 15% decrease in muscle mass following activin A 
overexpression in rat muscle, implicating activin A as a potential regulator of muscle 
mass.21 Other additional factors, either activin or undiscovered ligands, may be responsible 
for regulation of muscle size and, along with myostatin, may contribute to activin IIB 
receptor blockade–mediated muscle growth.
In transgenic mice that express a truncated activin IIB receptor under control of a muscle-
specific promoter, up to a 125% increase in skeletal muscle mass was observed at 7 months 
of age.22 These mice were crossed with mdx mice, and the resulting mice were found to 
have qualitatively larger muscles and improved myoblast transplantation efficiency.23 It is 
not clear from this study that activin IIB receptor blockade improves dystrophic pathology, 
as markers of disease progression, such as force production, fibrosis, and serum creatine 
kinase levels, were not reported. Injection of a soluble form of the activin IIB extracellular 
domain led to a 60% increase in skeletal muscle mass in normal mice and in a mouse model 
of amyotrophic lateral sclerosis by increasing skeletal muscle fiber size.18,24 Similarly, 
administration of recombinant activin IIB receptor to caveolin-3–deficient mice countered 
some muscle atrophy.25 Those studies showed that activin IIB receptor blockade increases 
skeletal muscle mass; however, a comprehensive functional evaluation of the effect of this 
approach on muscular dystrophy has not yet been reported.
To determine whether activin IIB receptor blockade is potentially therapeutic for muscular 
dystrophy, the effect of liver-mediated expression of a novel activin receptor inhibitor on 
muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy was 
assessed. Young mdx mice were injected with adeno-associated virus (AAV) containing a 
liver-specific promoter (LSP) and a transgene consisting of a soluble form of the activin IIB 
receptor fused to the fixed-chain region of IgG2a. At 5 months of age, a histological and 
functional assessment of the soleus, extensor digitorum longus (EDL), and diaphragm was 
made. Increased muscle mass was observed in all limb muscles with the exception of the 
soleus. Increased absolute but not specific force production was found in the EDL, whereas 
no changes were observed in the soleus or diaphragm. Analysis of muscle morphology 
revealed that muscle growth in the EDL was due to hypertrophy without hyperplasia. 
Echocardiography demonstrated no effect of the activin inhibitor on cardiac function. 
Although long-term studies are necessary, these results indicate activin receptor blockade is 
a safe and effective strategy for improving muscle size and function in muscular dystrophy.
METHODS
Vector Production
The activin IIB receptor–IgG2a extracellular domain fusion construct was subcloned into an 
AAV transfer vector with the α1-antitrypsin promoter with ApoE enhancer.18 The soluble 
activin receptor construct consists of the mouse myostatin signal sequence, the extracellular 
domain of the activin IIB receptor, and the fixed-chain region of IgG2a. Standard inverted 
terminal repeats (ITRs) flank the construct to permit packaging into AAV pseudotype 2/8. 
This promoter is liver-specific (abbreviated LSP) and was provided by Dr. Katherine High. 
AAV pseudotype 2/8 was produced by the University of Pennsylvania Vector Core as 
previously described.26
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Viral Injection of Mice
All animal experiments were approved by the University of Pennsylvania Animal Care and 
Use Committee. Six-week-old male mdx mice (n = 5 control, n = 5 treated) were injected 
with 1E12 genome copies of AAV 2/8 LSP.sActIIBr or saline via intraperitoneal injection. 
Following sedation with a ketamine–xylazine mixture, mice were injected intraperitoneally 
in the left lower quadrant of the abdomen with 1E12 genome copies of virus diluted in 300 
µl of saline or 300 µl of saline for controls. Mice were killed at 5 months of age and 
analyzed as described in what follows.
Muscle Morphology
For morphological analysis, muscles were embedded in optimal cutting temperature 
compound (Sakura Finetek, Torrance, California) and frozen in liquid nitrogen–cooled 
isopentane. Ten-micron-thick sections were cut, and the resulting slides were stored at 
−20°C. Immunohistochemistry was employed to determine the fiber sizes, fiber number, and 
myosin heavy chain (MHC) composition of the examined muscles, as described previously.3 
The MHC antibodies used to determine the MHC composition of selected muscles were type 
I (BA-F8) at 1:50, type IIA (SC-71) at 1:10, and type IIB (BF-F3) at 1:3. Sections were 
blocked in 5% bovine serum albumin/ phosphate-buffered saline (BSA/PBS) and incubated 
overnight in 5% BSA/PBS containing rabbit anti-laminin monoclonal antibody diluted 1:100 
(Neomarkers, Fremont, California) and an MHC primary antibody at the dilutions described 
earlier. Following washes in PBS, sections were incubated in appropriate secondary 
antibodies (Invitrogen, Carlsbad, California) for 1 hour in the dark at room temperature. 
Slides were washed and mounted with VectaShield with 4′-6-diamidino-2-phenylindole 
(DAPI). All images were captured and processed on a fluorescence microscope (Leitz 
DMRBE; Leica, Bannockburn, Illinois) equipped with a digital camera system (MicroMAX; 
Princeton Instruments, Trenton, New Jersey). Imaging software (OpenLab; Improvision, 
Waltham, Massachusetts) was used for quantification of fiber size. Centrally nucleated 
fibers were counted as fibers where the nucleus was closer to the center of the fiber than the 
periphery. The number of centrally nucleated fibers is presented as a percentage of the total 
number of fibers present in the muscle section.
Immunoblotting
For western blotting, muscles were dissected, weighed, and snap-frozen in liquid nitrogen. 
Muscles were crushed in a mortar and pestle on dry ice. Samples were then homogenized in 
lysis buffer [5 mM ethylene-diamine tetraacetic acid (pH 8), 50 mM Tris-Cl (pH 8), 150 
mM NaCl, 0.1% sodium dodecylsulfate (SDS), 1% Triton X-100, 0.5% deoxycholate, 50 
mM dithiothreitol (DTT), and Complete Protease Inhibitor Cocktail (Roche, Indianapolis, 
Indiana)]. Following incubation on ice for 10 min the protein homogenates were centrifuged 
at 12,000 rpm for 10 min. The supernatant was used for subsequent western blotting. Protein 
concentration was determined by protein assay (Bio-Rad, Hercules, California). Fifty 
micrograms of protein or 1.5 µl of serum was mixed with 2× SDS loading buffer [130 mM 
Tris (pH 8), 20% glycerol, 4.6% SDS, 2% DTT, 0.02% bromophenol blue], denatured at 
95°C for 10 min, and loaded onto 4–20% precast gels (PAGEr Gold; Lonza, Rockland, 
Maine). Proteins were transferred via the iBlot Dry Blotting System onto nitrocellulose 
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membranes (Invitrogen, Carlsbad, California). The membrane was then blocked with 5% 
nonfat dry milk in Tris-buffered saline containing 0.05% Tween 20. Immunoblotting was 
performed to detect activin IIB receptor (1:1000; Sigma, St. Louis, Missouri) and actin 
(1:2000; Sigma). Appropriate horseradish peroxidase–conjugated secondary antibodies were 
used at twice the dilution of primary antibody (GE Healthcare, UK). Protein detection was 
performed by exposure to chemiluminescence (Super Signal West Pico Chemiluminescent 
Substrate Kit; Pierce, Rockford, Illinois), and signal quantification was processed using 
densitometry software (Alpha Innotech, San Leandro, California).
Serum Creatine Kinase Activity
Serum creatine kinase (CK) levels were assessed with the indirect CK colorimetric assay kit 
according to the manufacturer’s protocol (Sigma).
Muscle Functional Analysis
The contractile properties of the soleus, extensor digitorum longus (EDL), and diaphragm 
were measured. Mice were anesthetized with ketamine/xylazine (80 and 10 mg/kg body 
weight, respectively) and exsanguinated. Blood samples were allowed to clot, centrifuged at 
2000 × g for 20 min, and then stored at −80°C for measurement of serum CK and circulating 
activin receptor. The EDL, soleus, diaphragm, quadriceps, and gastrocnemius muscles were 
removed and placed in a bath of Ringer solution gas equilibrated with 95% O2/5% CO2. The 
EDL, soleus, and diaphragm muscles were subjected to isolated mechanical measurements 
using a previously described apparatus (Aurora Scientific, Ontario, Canada).27 After 
determining optimum length (Lo) by supramaximal twitch stimulation, maximum isometric 
tetanus was measured. Upon completion of these measurements, muscles were weighed and 
rapidly frozen in melting isopentane for morphological analysis.
In Vivo Transthoracic Echocardiography
M-mode echocardiography was performed on mdx animals under ketamine/xylazine 
anesthesia using a 15- MHZ phased-array probe connected to a echocardiographic machine 
(Sonos 7500; Philips Medical Imaging, Andover, Massachusetts). In brief, an M-mode 
cursor was positioned in the parasternal short-axis view perpendicular to the interventricular 
septum and posterior wall of the left ventricle (LV) at the level of the papillary muscles, and 
M-mode images were obtained for measurement of LV end-diastolic and end-systolic 
dimension (LVDd and LVDs). The percentage of fractional shortening (%FS) was 
calculated from the equation: %FS = [(LVDd − LVDs) / LVDd] × 100. The end-diastolic 
and end-systolic volumes, ejection fraction, cardiac output, and stroke volume were 
calculated using the Teicholtz formulas.28 The same sonographer (M.S.), who was blinded 
to the treatment groups of the mice, performed all studies and the resulting calculations.
Statistical Analysis
The two-tailed unpaired Student’s t-test was used to compare means between experimental 
groups. Numerical data are reported as mean ± standard deviation. P < 0.05 was considered 
significant.
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The tissue distribution of the activin IIB receptor in the adult mouse was assessed by 
immunoblotting to determine what organ systems may be sensitive to activin IIB receptor 
blockade (Fig. 1a). The activin IIB receptor was expressed in a diversity of tissues as 
observed in the zebrafish and was found at the highest levels in the brain, heart, and skeletal 
muscle.29 The fast-twitch EDL notably contained more receptor than the slow-twitch soleus. 
The difference in receptor density may underlie the variance in phenotype of these muscles 
in the myostatin knockout mouse and their responsiveness to myostatin inhibition in adult 
animals.30 A viral construct was then designed to constitutively express a soluble form of 
the activin IIb receptor specifically from the liver (Fig. 1b). The liver-specific α1-antitrypsin 
promoter with apoE enhancer (LSP), previously used in our laboratory to express the 
myostatin propeptide from the liver, was paired with a soluble activin inhibitor.31 The 
inhibitor consists of the extracellular domain of the activin IIB receptor fused to the signal 
sequence from the mouse myostatin gene (sActIIBr). The fixed-chain region of IgG2a was 
appended to the inhibitor to confer additional stability to the recombinant protein.32
Six-week-old mdx mice (n = 5 controls, n = 5 treated) were injected with 1E12 genome 
copies of AAV 2/8 LSP.sActIIBr. Immunoblotting of serum samples 1 month after injection 
for activin IIBr demonstrated sActIIBr in the circulation (Fig. 1c). Quantitative 
immunoblotting using purified sActIIBr as a standard demonstrated that the amount of 
sActIIBr in the circulation of treated mice was 1.5 ± 1.6 ng/µl. In treated mdx mice, we 
observed increased body weight beginning at 1 month post-injection and continuing until the 
termination of the study at 5 months of age (Fig. 1d). Serum CK, a marker of membrane 
permeability and muscle damage, was reduced in the mdx/sActIIBr group (Fig. 1e). Reduced 
serum CK was also observed in short-term studies of myostatin inhibition in mdx mice, 
although the mechanism of this benefit is unclear.4,33,34
Activin receptor blockade resulted in increased weight of all skeletal muscles examined, 
with the exception of the soleus (Fig. 2). The gastrocnemius, tibialis anterior, and quadriceps 
had 39%, 46%, and 39% greater muscle mass than control, respectively (Fig. 2a). The EDL, 
a fast skeletal muscle, was 31% heavier, whereas the soleus, a slow skeletal muscle, was not 
significantly heavier (Fig. 2b). Muscle weights were normalized to body weight, and the 
ratio was increased in the gastrocnemius, tibialis anterior, and quadriceps (Fig. 2c). The 
muscle weight/body weight ratio was unchanged in the EDL and soleus (Fig. 2d). Heart 
weight and heart weight/body weight ratio were not affected by expression of sActIIBr (Fig. 
2a, c).
As the dystrophic process proceeds at different trajectories in different muscle groups, a 
functional and morphological analysis of representative muscles was undertaken. The EDL 
contains a large number of fast glycolytic fibers that express MHC type IIB and was selected 
as a fast muscle type. Similarly, the soleus contains a large proportion of slow oxidative 
fibers that express MHC type I and was chosen as a slow muscle type. The diaphragm is a 
severely affected skeletal muscle in the mdx mouse and recapitulates the course of the 
human disease.35 Also, the diaphragm contains a mixed population of fiber types consisting 
of mostly MHC type IIA/IIX fibers and is uniquely adapted to persistent use.36
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The functional properties of the EDL, soleus, and diaphragm were measured at the 
conclusion of the study (Fig. 3). In the mdx/sActIIBr group, the EDL exhibited 31% larger 
cross-sectional area (CSA) and 28% greater tetanic force production (Fig. 3b, c). 
Importantly, specific force, or tetanic force normalized to CSA, was not compromised by 
sActIIBr overexpression (16.4 ± 3.6 in control mdx vs. 16.2 ± 2.4 N/cm2 in mdx/sActIIBr). 
The soleus demonstrated similar CSA (1.53 ± 0.17 vs. 1.65 ± 0.18 mm2), tetanic force 
production (223 ± 54 vs. 266 ± 52 mN), and specific force (14.6 ± 3.4 vs. 16.2 ± 3.1 N/cm2). 
No difference in specific force was observed in the diaphragm (5.6 ± 0.8 vs. 5.5 ± 0.4 
N/cm2).
To determine the mechanism of muscle growth mediated by activin receptor blockade, 
morphological analysis of representative muscle groups was undertaken. The EDL exhibited 
increased mean fiber size (Fig. 3a) without change in fiber number (828 ± 209 vs. 870 ± 90 
fibers). These results indicate that muscle growth was due to hypertrophy without 
hyperplasia in the EDL. Sagittal fiber number (11.8 ± 2.5 vs. 12.3 ± 2.3 fibers) and the mean 
fiber size of type I, type IIA, type IIB, and total fibers in the diaphragm were not altered by 
overexpression of sActIIBr (Fig. 3d). The proportion of centrally nucleated fibers, an 
indicator of previously regenerated fibers, were assessed and found to be unchanged in the 
mdx/sActIIBr EDL (57.6 ± 6% vs. 54.3 ± 8% of total fibers) and diaphragm (13.3 ± 6.5 vs. 
13.3% ± 2.5 percent of total fibers). Thus, activin blockade did not alter any measured 
parameter in the diaphragm and increased muscle fiber size in the EDL. Fiber size, fiber 
number, MHC composition, and the proportion of centrally nucleated fibers were unaltered 
in the mdx/sActIIBr soleus (data not shown).
As the activin IIB receptor is expressed in the heart at levels comparable to skeletal muscle, 
we investigated whether there was any functional effect of activin blockade on the heart at 
the study endpoint by echocardiography. No differences were observed in heart rate (419 ± 
53 in control mdx vs. 374 ± 60 in mdx/sActIIBr), LV inner dimension at diastole (0.33 ± 
0.02 vs. 0.36 ± 0.05), LV inner dimension at systole (0.2 ± 0.04 vs. 0.24 ± 0.06), end-
diastolic volume (0.09 ± 0.02 vs. 0.13 ± 0.05), or end-systolic volume (0.03 ± 0.01 vs. 0.04 
± 0.03). Also, fractional shortening (38 ± 7.5% vs. 35 ± 7.0%) and ejection fraction (74 ± 
8.1 vs. 73 ± 10.4) were unchanged. These data indicate that overexpression of circulating 
sActIIBr did not affect cardiac function in young mdx mice.
DISCUSSION
This study is the first demonstration of the effect of activin receptor blockade in a model of 
Duchenne muscular dystrophy. The soluble activin receptor approach has been exploited to 
increase muscle growth in normal mice and models of primary neurological disorders to 
varying effect.18,24,37 Herein we have shown that liver-mediated expression of a soluble 
activin IIB inhibitor in mdx mice leads to increased muscle size and strength as well as 
reduced serum CK levels. Numerous studies have shown beneficial effects of myostatin 
inhibition on mild muscular dystrophy as typified by the mdx model.4,17,33 However, early 
enthusiasm for this approach has been tempered by equivocal results in more severe mouse 
models and humans.6,33,38 In comparison to myostatin-specific inhibition, the activin IIB 
receptor binds to and is capable of inhibiting additional ligands such as activin, inhibin, and 
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GDF11.16 GDF11 and activin A/B have been shown to influence myotube differentiation in 
vitro, yet definitive evidence of their role in the regulation of muscle formation or size in 
vivo is lacking.16,20 Modulation of these divergent signaling pathways may additively 
increase muscle mass and delay the pathological progression of muscular dystrophy. It 
should be emphasized that interventions that increase muscle size without stabilization of 
the sarcolemma do not appear to alter the inherent susceptibility of dystrophic muscle to 
contraction-induced damage.3 Rather, the number of motor units required to produce a given 
amount of force is reduced. As contraction-induced damage is thought to be the predominant 
mechanism of muscle loss in muscular dystrophy, reducing the number of motor units 
recruited to produce force may slow the loss of functional muscle mass.39
The increased skeletal muscle mass observed in our study was due to hypertrophy without 
hyperplasia and is comparable to prior studies of myostatin inhibition studies in mdx 
mice.17,33 The EDL, a representative fast muscle type, responded more robustly to activin 
receptor blockade than the soleus, a representative slow muscle type, as demonstrated by an 
increase in muscle weight and mean fiber size. The increased weight of the EDL occurred 
via an increase in size of existing fibers (hypertrophy) without a change in the number of 
muscle fibers (hyperplasia). Muscle growth due to hypertrophy and not hyperplasia is 
consistent with prior studies of postnatal myostatin inhibition.40,41 The EDL displayed 
increased absolute force production with no change in force production normalized to CSA 
(specific force). Thus, activin blockade increases muscle size in fast-twitch muscle without 
the compromised contractile function seen in the myostatin knockout EDL.42 In contrast, the 
soleus and diaphragm did not show any change in fiber size or muscle strength. Fast muscle 
fibers and muscle types appear to preferentially respond to the absence or postnatal 
inhibition of myostatin, as observed in the myostatin knockout mouse and studies of 
myostatin inhibition in the mdx mouse.30,31,43 The etiology of the reduced response in the 
soleus and slow muscle fibers is unknown; however, it may be related to the fiber type–
dependent differential expression of the activin IIB receptor, as reported here and 
elsewhere.30 An equally plausible explanation for the observed non-responsiveness to 
activin receptor blockade in the diaphragm is that aerobic adaptation to persistent use limits 
the capacity of the fast fibers to hypertrophy. The fast fibers in the diaphragm are uniquely 
adapted for constant use and are dependent on oxygen diffusion and consumption for 
adenosine triphosphate production.36 In contrast, the EDL contains fast fibers dependent on 
glycolytic metabolism for energy production. Hence, it is possible that the equivalent fast 
fibers in the diaphragm will not respond as robustly to activin receptor blockade due to a 
size limitation imposed by aerobic dependence.
Although activin IIB receptor blockade leads to massive skeletal muscle hypertrophy and 
ameliorates some aspects of dystrophic pathology, the potential effects in other organ 
systems should be addressed in future studies. The activin IIB receptor approach or 
expression of other circulating binding proteins, such as follistatin, follistatin-related gene 
(FLRG), and growth and differentiation factor-1 (GASP-1), do generate rapid and 
impressive gains in muscle mass. However, long-term use may be precluded by impaired 
signaling of other TGF-β family members.22,44–46 The activin IIB receptor is expressed in 
the brain, heart, liver, and gonads, as well as in skeletal muscle of the zebrafish, and has a 
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similarly diverse expression profile in the adult mouse (Fig. 1).29 The broad tissue 
distribution of the activin IIB receptor and its diverse ligands suggest complete interference 
with signaling through the receptor may result in maladaptive abnormalities in other organ 
systems such as the liver, pancreas, and gonads. For example, adenoviral expression of a 
truncated activin IIB receptor in the liver resulted in transiently increased liver weight and 
decreased serum cholesterol and albumin.47 Analysis of activin IIB receptor– deficient mice 
crossed to Smad2-deficient mice revealed smaller pancreatic islet size and reduced insulin 
content.48 Studies of the TGF-β antagonist follistatinlike-3 transgenics revealed potentially 
adverse effects on metabolic homeostasis and reproductive function.49,50 Another 
consideration is the effect of reduced activin receptor signaling on the heart. The influence 
of activin IIB receptor ligands, such as myostatin, on cardiac size and function is 
disputed.51,52 Our findings indicate activin receptor blockade has no acute effect on cardiac 
function. To ensure the safety of this approach on normal and dystrophic cardiac physiology, 
long-term studies are required.
Activin receptor blockade is a potential therapeutic modality for a wide range of muscle 
disorders that should be further investigated in preclinical studies. The response of murine 
dystrophic models to myostatin inhibition has been variable depending on the nature of the 
primary defect and severity of disease progression.38,53,54 Activin receptor blockade, by 
inhibiting additional activin receptor ligands, may afford greater resistance to dystrophic 
damage than myostatin inhibition alone. For Duchenne muscular dystrophy, canine models 
that accurately recapitulate the course of human disease are available to test the efficacy of 
activin blockade.55,56 As therapeutic liver transduction by AAV has been shown in a canine 
model of hemophila B, it is feasible that our approach could be translated to a dystrophic 
dog model by creating a species-specific transgene.57 Aberrant signaling through the activin 
receptors has been implicated in many other disorders such as cachexia, diabetes, disuse 
atrophy, and sarcopenia.58 Although the effect of myostatin inhibition has been described in 
some of these disease states, further benefit may accrue with more complete activin receptor 
inhibition as is likely achieved with our method. Additional studies are underway to directly 
compare the effect of postnatal myostatin inhibition and activin receptor blockade in normal 
and dystrophic mice.
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EDL extensor digitorum longus
FLRG follastin-related gene
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Expression of soluble activin IIB receptor in mdx mice. (a) Tissue distribution of the activin 
IIB receptor assessed by immunoblotting. (b) A schematic of the AAV construct used in this 
study. (c) Six-week-old mdx mice (n = 5 control, n = 5 treated) were injected 
intraperitoneally with 1E12 genome copies of AAV 2/8 LSP.sActIIBr or saline. 
Immunoblotting of control (C) and treated (T) serum samples 1 month after injection 
demonstrates the presence of circulating sActIIBr. (d) Significantly increased body weight 
was noted in the mdx/sActIIBr group (shown in red) in comparison to control mdx mice 
(shown in blue) from 1 month post-injection until the conclusion of the study. (e) Activin 
receptor blockade significantly reduced serum CK from 3095 ± 1139 U/L in controls (blue 
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bar) to 1404 ± 409 U/L in treated mice (red bar). Br, brain; Ki, kidney; Li, liver; Ht, heart; 
Dia, diaphragm; EDL, extensor digitorum longus; SOL, soleus. *P < 0.05. [Color figure can 
be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Effect of soluble ActIIBr expression on muscle weight in mdx mice. (a) Treatment with 
sActIIBr increased the muscle mass of the tibialis anterior (TA) by 46%, the gastrocnemius 
(GAS) by 39%, and the quadriceps (QUAD) by 39%. No difference in heart weight was 
observed in the mdx/sActIIBr group. (b) The EDL demonstrated a 31% gain of muscle mass, 
whereas the soleus (SOL) wet weight did not change. (c, d) The ratio of muscle weight to 
body weight was increased in the TA, GAS, and QUAD muscles, whereas the ratio was 
unchanged in the heart, EDL, and soleus. Blue bars represent data from control mdx mice (n 
= 5); red bars represent data from mdx/sActIIBr mice (n = 5). *P < 0.05. TA, tibialis 
anterior; GAS, gastrocnemius; QUAD, quadriceps; SOL, soleus. [Color figure can be 
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Morphometric and functional properties of the EDL and diaphragm. (a) The mean fiber size 
of the EDL was larger in the mdx/sActIIBr group. Representative hematoxylin and eosin–
stained muscle sections are shown. Scale bar: 100 µm. (b) The cross-sectional area of the 
EDL was increased from 2.6 ± 0.2 to 3.4 ± 0.5 µm2 in treated mice. (c) An increase in 
tetanic force production (430 ± 96 vs. 549 ± 91 mN) was observed in the treated EDL. (d) In 
the diaphragm, the mean fiber sizes of type I, type IIA, type IIB, and total fibers were not 
altered by overexpression of soluble activin receptor. Representative hematoxylin and 
eosin–stained muscle sections are shown. Scale bar: 50 µm. Blue bars represent data from 
control mdx mice (n = 5); red bars represent data from mdx/sActIIBr mice (n = 5). *P < 
0.05. [Color figure can be viewed in the online issue, which is available at 
wileyonlinelibrary.com.]
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